REGN - Regeneron wins approval for rare immune disease therapy pozelimab
2023-08-18 14:23:01 ET
More on Regeneron Pharmaceuticals
-
Regeneron could see share price bounce with potential approvals
-
Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening
- Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront
- Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check
For further details see:
Regeneron wins approval for rare immune disease therapy pozelimab